Navigation Links
Gerson Lehrman Group and iGuard, Inc. Partner to Offer Patients a Voice in Healthcare Industry Decisions
Date:5/15/2008

NEW YORK, May 15 /PRNewswire/ -- Gerson Lehrman Group, the world's leading marketplace for expertise, today announced a partnership with iGuard.org, a Web-based community devoted to providing patients with the medication information they need to actively manage their own healthcare. iGuard.org provides personalized iGuard Risk Ratings, iGuard Safety Alerts, and a forum for patients to share their experience with other registered users who also want to get informed, stay informed, and share feedback about their medications.

Through this collaboration, Gerson Lehrman Group's clients, including many of the world's leading professional service firms, corporations, nonprofits, and financial services firms will now be able to tap the collective experience of iGuard.org's online patient community through surveys and research projects.

"We are very pleased to enter into this unique partnership with iGuard.org. By leveraging Gerson Lehrman Group's established Web-based tools and platforms, we can now provide the world's leading decision makers with an organized, effective approach to tap into a large patient community," said Alexander Saint-Amand, President and CEO of Gerson Lehrman Group. "Through this relationship, we can take an important step toward including patients' voices when educating professionals, so that they can make more informed healthcare decisions."

"We have seen tremendous response from the patient community to our mission of increasing and improving communication," said Hugo Stephenson, MD, Founder and President of iGuard.org. "This relationship with Gerson Lehrman Group is a natural extension of that effort, enabling patients to share their thoughts and preferences with those entities that can affect changes in the healthcare industry."

This collaboration brings together more than 175,000 experts in the GLG Councils with over 200,000 patients who are members of the iGuard.org community, providing decision makers with th
'/>"/>

SOURCE Gerson Lehrman Group
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Tiens Biotech Group (USA) Reports First Quarter Results
2. National Business Group on Health Awards Gold to Blue Cross and Blue Shield of Minnesota for Promoting a Healthy Workplace
3. HealthSouth to Present at the 2008 Citigroup Global Healthcare Conference and Jefferies 2nd Annual Healthcare Conference
4. Triangle Group Raises Awareness of Fibromyalgia
5. Simcere Pharmaceutical Group Announces SFDA Approval of First-to-Market Generic Biapenem Injection Anxin
6. National Business Group on Health Honors Data Recognition Corporation as One of Best Employers for Healthy Lifestyles
7. Sanofi-aventis Named One of Best Employers for Healthy Lifestyles by National Business Group on Health
8. BIOCOM Purchasing Group Brings in Four New Contracts
9. The Quantum Group Executes First Medicaid Service Contract with HMO
10. Florida Hospital Group Pays U.S. $7,775,000 to Settle False Claims Act Allegations
11. Senior Citizens, Unions, Physicians and Nurses Groups Lend Support to Hospitals State House Rally
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Express Scripts Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of WellPoint's NextRx Subsidiaries 2Health News:CVS/pharmacy Introduces New Coupon Center on CVS.com 2Health News:Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program 2Health News:Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program 3Health News:Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program 4Health News:Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program 5Health News:Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program 6Health News:Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer 2Health News:Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer 3Health News:Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer 4Health News:Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer 5Health News:Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer 6Health News:Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer 7Health News:Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer 8Health News:iUniverse Hosts Canadian Storytellers, Cystic Fibrosis Awareness Advocate for BookExpo America 2009 Book Signings 2Health News:New Website, ElasticBandageStore.com, Offers Elastic Bandages at Wholesale Prices 2
Breaking Medicine Technology:RecoverCare Announces the Relocation of Corporate Headquarters to Louisville 2RecoverCare Announces the Relocation of Corporate Headquarters to Louisville 3AMP Receives $1.4 Million Grant From the Bill & Melinda Gates Foundation to Improve Advocacy for VACCINES and Immunization Systems in West Africa 2AMP Receives $1.4 Million Grant From the Bill & Melinda Gates Foundation to Improve Advocacy for VACCINES and Immunization Systems in West Africa 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Marc Russo Named Vice President of Senior Markets at Blue Shield of California 57132 1Marc Russo Named Vice President of Senior Markets at Blue Shield of California 57132 2MUSC Researchers Concerned About Online Drug Availability 57128 1MUSC Researchers Concerned About Online Drug Availability 57128 2HealthSouth Declares Dividend on 6 5 25 Series A Convertible Perpetual Preferred Stock 57123 1